Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459482 · ClinicalTrials.gov registry record · NA
Endpoint Determination Study Protocol
A NA study, sponsored by Biomerica.
- Completed
- Registry status
- NA
- Development phase
- 556
- Enrollment target
NCT03459482: Completed NA study, sponsored by Biomerica.
NCT03459482 is a NA study that has completed, run by Biomerica. The registered enrollment target is 556 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03459482, a NA study, has completed, sponsored by Biomerica.
- COMPLETED
- Registry status
- NA
- Development phase
- 556 participants
- Enrollment target
Study Summary
This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.
Primary Outcome
Abdominal pain intensity will be measured daily using an 11-point (0-10) numeric rating scale (NRS) that asks subjects to rate their worst abdominal pain over the past 24-hours.
Interventions
- OTHER Food Elimination Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 556 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2021-12-31 |
| Phase | NA |
What the finished NCT03459482 record still lists
NCT03459482 is an interventional study that assigns participants to a tested intervention. The registered 556 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 1 intervention - of which Food Elimination Diet is the first listed.
NCT03459482 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03459482 about?
NCT03459482 is a clinical study titled "Endpoint Determination Study Protocol". This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.
What is the current status of trial NCT03459482?
This trial is currently completed. It is a NA study. The enrollment target is 556 participants. The study started on 2018-06-21. Estimated completion is 2021-12-31.
What interventions are being tested in trial NCT03459482?
The interventions under investigation include: Food Elimination Diet (OTHER).
Who is sponsoring clinical trial NCT03459482?
This trial is sponsored by Biomerica, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03459482's enrollment target sits among peer trials
556 184th of 2000 higher than 1,817 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
- NCT05708885 · 557 participants · NA
Striated Esophageal Motor Function Modulation in Health and Disease
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI